AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang

The FDA's leadership vacuum just got deeper — CDER acting director Tracy Beth Høeg is expected to leave the agency, putting three top positions in temporary hands simultaneously.

Plus Roche lands a ctDNA-guided Tecentriq approval that could reshape adjuvant bladder cancer treatment, and oral Wegovy prescriptions dip for the first time. Packed Friday.

Welcome to The Pharma Closeout for Friday, May 15, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Three days after we covered Commissioner Makary's resignation, the next domino falls. Breaking this afternoon — Endpoints News, confirmed by Reuters through three sources familiar with internal planning — Tracy Beth Høeg, the acting director of CDER, is expected to depart the FDA. Høeg had only been in the acting director role since Pazdur's departure last December. That now puts temporary directors in three top agency positions simultaneously, with no named successors for any of them.

She came in as a controversial pick — Endpoints characterizes her as a known skeptic of vaccines and antidepressants. For the center that evaluates every drug application in the country, that profile raised eyebrows from day one. Her departure may not surprise anyone inside the building, but the compounding vacancies create a real governance gap.

And the structural concern goes beyond personnel. Makary's tenure introduced multiple new policy initiatives — including the drug approval accelerator pilot we've been tracking on this show. Without senior leadership to champion those programs and defend them against political headwinds, their futures are uncertain. BioPharma Dive frames this as a leadership void that leaves biotech with renewed uncertainty — and that framing is hard to argue with.

I'd push back on the idea that everything grinds to a halt, though. CDER's review divisions are staffed by career scientists who've navigated multiple leadership transitions. The PDUFA clock keeps ticking. Individual drug reviews move forward. The operational machinery doesn't seize up because the acting director walks out.

Fair — the day-to-day review work continues. But the policy layer freezes. Companies making strategic decisions about filing pathways, accelerated designations, advisory committee engagement — they're operating without a compass right now. And that compounds over time.

What's revealing is the reaction. Biotech leaders are already campaigning for Pazdur to return, per BioPharma Dive's reporting. That tells you where the industry's confidence sits. Until these seats have permanent, credible occupants, every policy initiative from the past six months is effectively provisional — and smart companies are planning accordingly.

And while the FDA sorts out its org chart, the deal and pipeline side delivered today. Daiichi Sankyo and AstraZeneca's Enhertu picked up two new FDA approvals in HER2-positive early breast cancer, per Business Wire. That includes post-neoadjuvant treatment for patients with residual invasive disease. This moves Enhertu decisively from the metastatic setting into early-stage disease — a dramatically larger addressable population.

Early-stage was always Enhertu's commercial endgame. Metastatic revenue gets you to blockbuster status. Early breast cancer revenue is what builds a mega-blockbuster franchise. And this puts direct pressure on Kadcyla in the adjuvant HER2-positive space — expect the treatment algorithm conversation in community oncology to shift.

Also this week — Rigel Pharmaceuticals picked up exclusive global rights to Veppanu from Arvinas and Pfizer. Eighty-five million dollars upfront. Veppanu was approved May first for ER-positive, HER2-negative, ESR1-mutated breast cancer. Endpoints characterized this as Pfizer and Arvinas handing off a disappointing asset.

Disappointing at Pfizer's scale, maybe. But Rigel reported solid Q1 revenue with a return to net profitability in the quarter. They're a commercial-stage company that can build a targeted franchise without needing blockbuster volume to justify the investment. Different economics entirely.

Couple of quick pipeline hits. United Therapeutics received FDA clearance for its UHeart xenotransplantation clinical trial — a genetically modified pig heart heading into formal human studies. Their UKidney IND was cleared back in February 2025, so this is the cardiac counterpart. If United Therapeutics can build the cardiac program the way they've advanced the renal side, xenotransplantation moves from compassionate-use headlines to a structured clinical development pathway.

And worth noting — Biogen is pushing its tau-targeting drug BIIB080 into late-stage testing despite a Phase 2 Alzheimer's study that missed key endpoints. They're citing the strength of biomarker and efficacy signals underneath the topline result. That's the kind of decision that either looks visionary in hindsight or becomes a cautionary tale about reading too much into subgroup trends.

Two more. Create Medicines raised a hundred and twenty-two million for in vivo RNA-based CAR-T therapies targeting cancer and autoimmune conditions. And Takeda confirmed plans to lay off forty-five hundred workers in a broader restructuring — a reminder that even large pharma isn't immune to the cost discipline that's been sweeping the sector.

On the regulatory side, the approval that deserves the most attention today is Roche's Tecentriq in bladder cancer. The FDA approved Tecentriq for adjuvant treatment of muscle-invasive bladder cancer after cystectomy — specifically for patients with detectable ctDNA molecular residual disease, identified using Natera's Signatera as a companion diagnostic.

So the FDA is formally endorsing a biomarker-guided treatment paradigm in this setting — use blood-based MRD testing to select which post-surgical patients receive adjuvant immunotherapy, and spare the rest.

The data is what carries it. Per the filing, a thirty-six percent reduction in disease recurrence or death and a forty-one percent reduction in the risk of death in ctDNA-positive patients identified by serial testing within one year of cystectomy. Now — the fact that the OS hazard reduction exceeds DFS. That's the number that will get attention in tumor boards. You're not simply catching early molecular relapsers who would have been picked up clinically anyway. You're selecting a population where checkpoint response is durable enough to convert into a real survival separation. That distinction matters for how this biomarker gets adopted outside academic centers.

And this approval lands right next to the AstraZeneca VOLGA data we covered yesterday. The treatment landscape in muscle-invasive bladder cancer is layering up fast, with Merck's Keytruda PDUFA still ahead on August seventeenth for cisplatin-eligible disease.

Also worth noting on the regulatory front — the FDA placed a full clinical hold on Aardvark Therapeutics' ARD-101 for Prader-Willi syndrome, halting all late-stage trials. This follows a cardiovascular event in a healthy volunteer that prompted Aardvark to voluntarily pause the program earlier this year. The full hold now makes it official. Prader-Willi remains one of the most underserved rare disease populations, and losing a late-stage candidate stings.

Separately, the Supreme Court temporarily restored telehealth access to mifepristone by mail while litigation continues — a ruling that maintains the current prescribing framework for now but leaves the longer-term question unresolved.

And one commercial signal to close the week. FiercePharma's oral GLP-1 tracker reports Novo Nordisk's oral Wegovy saw total prescriptions decline for the first time since launch. No specific numbers published, but the directional signal is what matters. Whether this reflects supply normalization, displacement from Lilly's Foundayo, or early prescription cycling — it's the first downward data point in what had been an unbroken growth curve. The Lilly-Novo oral obesity framing we've been tracking all quarter is starting to show up in the prescription data.

Looking ahead — the FDA leadership situation is the dominant variable for this industry right now. No successor has been named for CDER. Three top positions in temporary hands. Every pending policy initiative sits in limbo until that changes. Watch for whether the White House moves on a permanent nominee, or whether this vacuum persists into the summer.

And keep the bladder cancer space on your radar. Between today's Tecentriq ctDNA approval and AstraZeneca's VOLGA data, treatment algorithms in muscle-invasive disease are getting substantially more complex. Merck's Keytruda PDUFA on August seventeenth will reshape the picture again — the sequencing questions here are moving faster than guidelines can keep up.

That is your Pharma Closeout for Friday, May fifteenth. FDA leadership fractures further with Høeg's expected exit from CDER, Roche lands a precision ctDNA-guided Tecentriq approval, Enhertu pushes into early breast cancer, Biogen doubles down on tau despite a Phase 2 miss, and oral Wegovy scripts dip for the first time. If this briefing saves you time, follow us on Spotify and drop a rating — it's the single best way to help more people across this industry find us. We'll be back Sunday with the full week in review.

Go enjoy the weekend, everyone. We'll pull the whole week together on Sunday — see you then.